Erin Pennock Foff Sells 4,438 Shares of Maplight Therapeutics (NASDAQ:MPLT) Stock

by · The Cerbat Gem

Maplight Therapeutics, Inc. (NASDAQ:MPLT – Get Free Report) insider Erin Pennock Foff sold 4,438 shares of the firm’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $28.54, for a total transaction of $126,660.52. Following the completion of the transaction, the insider directly owned 346,059 shares of the company’s stock, valued at approximately $9,876,523.86. This trade represents a 1.27% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Erin Pennock Foff also recently made the following trade(s):

  • On Wednesday, May 6th, Erin Pennock Foff sold 24,052 shares of Maplight Therapeutics stock. The shares were sold at an average price of $28.76, for a total transaction of $691,735.52.
  • On Tuesday, May 5th, Erin Pennock Foff sold 10,576 shares of Maplight Therapeutics stock. The shares were sold at an average price of $28.20, for a total transaction of $298,243.20.
  • On Monday, May 4th, Erin Pennock Foff sold 15,652 shares of Maplight Therapeutics stock. The shares were sold at an average price of $27.96, for a total transaction of $437,629.92.

Maplight Therapeutics Price Performance

Maplight Therapeutics stock traded up $2.69 during mid-day trading on Monday, reaching $30.09. The company’s stock had a trading volume of 288,241 shares, compared to its average volume of 312,441. The stock has a market cap of $1.28 billion and a P/E ratio of -0.76. Maplight Therapeutics, Inc. has a 12 month low of $12.24 and a 12 month high of $33.28. The firm’s 50 day simple moving average is $23.27.

Maplight Therapeutics (NASDAQ:MPLT – Get Free Report) last released its earnings results on Thursday, March 26th. The company reported ($2.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.05) by ($1.42). As a group, analysts predict that Maplight Therapeutics, Inc. will post -3.96 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Canaccord Genuity Group assumed coverage on shares of Maplight Therapeutics in a research note on Thursday, March 19th. They issued a “buy” rating and a $35.00 price target for the company. Needham & Company LLC assumed coverage on shares of Maplight Therapeutics in a research note on Wednesday, April 8th. They issued a “buy” rating and a $37.00 price target for the company. Weiss Ratings assumed coverage on shares of Maplight Therapeutics in a research note on Thursday, January 22nd. They issued a “sell (e)” rating for the company. Wall Street Zen cut shares of Maplight Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Finally, HC Wainwright assumed coverage on shares of Maplight Therapeutics in a research note on Monday, May 4th. They issued a “buy” rating and a $45.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $34.43.

Read Our Latest Stock Analysis on MPLT

Institutional Trading of Maplight Therapeutics

A number of hedge funds have recently modified their holdings of MPLT. Strs Ohio acquired a new stake in shares of Maplight Therapeutics during the 4th quarter worth about $53,000. Blue Owl Capital Holdings LP acquired a new stake in shares of Maplight Therapeutics during the 4th quarter worth about $5,745,000. Geode Capital Management LLC acquired a new stake in shares of Maplight Therapeutics during the 4th quarter worth about $6,835,000. Seven Grand Managers LLC acquired a new stake in shares of Maplight Therapeutics during the 4th quarter worth about $1,756,000. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Maplight Therapeutics during the 4th quarter worth about $34,026,000.

About Maplight Therapeutics

(Get Free Report)

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.

See Also